Health AI Central
Share:
Peer-Reviewed Publication
Heart2025;111(21):1029-1035.October 14, 2025Journal Article

Clinical implementation of an AI-enabled ECG for hypertrophic cardiomyopathy detection.

Christopher J Love1, Joshua Lampert2, David Huneycutt3, Dan L Musat4, Mahek Shah5, Jorge E Silva Enciso6, Bryan Doherty3, James L Gentry3, Michael D Kwan5, Ethan C Carter7, Vivek Y Reddy2
1Viz Ai Inc, San Francisco, California, USA cjlove.mit@gmail.com.
2Mount Sinai Fuster Heart Hospital, New York, New York, USA.
3TriStar Centennial Medical Center, Nashville, Tennessee, USA.
4Valley Hospital, Ridgewood, New Jersey, USA.
5Methodist Healthcare System of San Antonio Ltd, San Antonio, Texas, USA.
6UC San Diego Health, San Diego, California, USA.
7Viz Ai Inc, San Francisco, California, USA.
PubMed DOI

Abstract

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is often underdiagnosed. Artificial intelligence (AI)-based notification of HCM suspicion on a 12-lead ECG has been proposed to assist patient identification and evaluation. However, there has been no study to date to assess clinical implementation of this approach. METHODS: In an open-label, multicentre prospective cohort study, Viz HCM (Viz.ai)-an A…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.